^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAG72-CAR T

    i
    Other names: TAG72-CAR T, TAG72-Targeting Chimeric Antigen Receptor (CAR) T
    Associations

    News

    Trials
    Company:
    City of Hope
    Drug class:
    TAG72-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    8ms
    Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date • Platinum resistant
    |
    cyclophosphamide • fludarabine IV • TAG72-CAR T
    almost3years
    Effective Targeting of Gastric Cancer Peritoneal Metastases with Cytokine-Endowed TAG72-Directed CAR T Cells (ASGCT 2023)
    Molecular heterogeneity of GC and poor immunogenicity of peritoneal immune tumor microenvironment (TME) limit the benefits of existing immunotherapeutic strategies that include trastuzumab (anti-HER2), ramucirumab (anti-VEGF), pembrolizumab, and nivolumab (anti-PD-1). Additionally, our newly engineered TAG72-CAR T cells with a membrane-bound version of the IL-12 (mbIL12) cytokine significantly enhanced anti-tumor efficacy of TAG72-CAR T cells leading to more durable in vivo therapeutic responses. A novel immunotherapeutic combination using autologous mbIL12-engineered TAG72-CAR T cell therapy is a promising strategy to help overcome the therapeutic failures in GCPM patients.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Cyramza (ramucirumab) • TAG72-CAR T
    almost3years
    Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2026 --> Apr 2027 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    HRD • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • TAG72-CAR T
    almost3years
    Engineering TAG72-CAR T cells as a therapeutic strategy in the hen - a spontaneous, preclinical model for ovarian cancer (AACR 2023)
    In this study, chicken TAG72-CAR T cells were successfully generated, characterized, and tested as a therapeutic approach for treating OvCa in the hen, and will be further used to evaluate their in vivo efficacy in the hen model. The ability to test therapeutic strategies in an in vivo model that biologically and physiologically parallels the disease in women allows for the improvement of OvCa diagnosis and prognosis.
    Preclinical • CAR T-Cell Therapy
    |
    TAG72-CAR T
    over3years
    Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Nov 2026 | Trial primary completion date: Dec 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    HRD (Homologous Recombination Deficiency) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • BRCA (Breast cancer early onset) • IL10 (Interleukin 10)
    |
    HRD • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • TAG72-CAR T
    over3years
    Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    HRD (Homologous Recombination Deficiency) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • BRCA (Breast cancer early onset) • IL10 (Interleukin 10)
    |
    HRD • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • TAG72-CAR T
    almost4years
    Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, City of Hope Medical Center | Initiation date: Feb 2022 --> Jun 2022
    Trial initiation date • CAR T-Cell Therapy
    |
    HRD (Homologous Recombination Deficiency) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • BRCA (Breast cancer early onset) • IL10 (Interleukin 10)
    |
    HRD • BRCA mutation
    |
    cyclophosphamide • fludarabine IV • TAG72-CAR T